May 14 2021

INOVOTION’S NEW ASSAY

IMMUNO-ONCOLOGY, TARGETING CD20

 

 

INOVOTION has a new in vivo assay for Anti-CD20 therapies and B-Cell targeting.

Our R&D team has recently set up and validated a highly specific new assay based on Rituximab and

Daudi cells on chicken embryos.

This changes the landscape by opening a large range of possibilities for rapidly evaluating anti-CD20

therapies and combinations.

Let’s talk about your projects to see how this new assay will further your R&D !!

Feel free to also contact us directly via our contact page.

All our news